The latest price target for Actuate Therapeutics (NASDAQ:ACTU) was reported by HC Wainwright & Co. on March 17, 2025. The analyst firm set a price target for $20.00 expecting ACTU to rise to within 12 months (a possible 168.82% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Actuate Therapeutics (NASDAQ:ACTU) was provided by HC Wainwright & Co., and Actuate Therapeutics initiated their buy rating.

There is no last upgrade for Actuate Therapeutics

There is no last downgrade for Actuate Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Actuate Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Actuate Therapeutics was filed on March 17, 2025 so you should expect the next rating to be made available sometime around March 17, 2026.

While ratings are subjective and will change, the latest Actuate Therapeutics (ACTU) rating was a initiated with a price target of $0.00 to $20.00. The current price Actuate Therapeutics (ACTU) is trading at is $7.44, which is within the analyst’s predicted range.